Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 6:46 pm Unchanged | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | BCLS II Equity Opportunities LP | 0 0.000% | 0 (Unchanged) | Filing History |
| 2023-02-14 06:04 am Purchase | 2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BCLS II Equity Opportunities LP | 213,908 8.700% | 100,000 (+87.79%) | Filing History |
| 2022-02-14 06:40 am Purchase | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BCLS II Equity Opportunities LP | 113,908 5.800% | 5,908 (+5.47%) | Filing History |
| 2020-06-09 11:45 am Purchase | 2020-04-30 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BCLS II Equity Opportunities LP | 108,000 6.100% | 108,000 (New Position) | Filing History |